CSL Behring LLC / uniQure biopharma BV merger inquiry
The CMA investigated a commercialisation and licensing agreement relating to AMT-061 between CSL Behring LLC and uniQure biopharma BV.
Statutory timetable
| Phase 1 Date | Action |
|---|---|
| 27 November 2020 | Decision published |
| 6 November 2020 | Launch of merger enquiry |
| 6 November 2020 to 20 November 2020 | Invitation to comment |
Phase 1
Found not to qualify decision announced
24 November 2020: The CMA has decided that the commercialisation and licensing agreement relating to AMT-061 between CSL Behring LLC and uniQure biopharma BV does not qualify for investigation under the merger provisions of the Enterprise Act 2002.
- (27.11.20)
Launch of merger inquiry
6 November 2020: The CMA announced the launch of its merger inquiry by notice to the Parties.
- (6.11.20)
Invitation to comment closes: 20 November 2020
The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services. The CMA has reached the preliminary view that this transaction will not result in the creation of a relevant merger situation because it will not result in two or more enterprises ceasing to be distinct.
To assist it with this assessment, the CMA invites comments on the transaction from any interested party.
These comments should be provided by the deadline set out above.
Contact
Please send written representations about any competition issues to:
Updates to this page
Published 6 November 2020Last updated 27 November 2020 + show all updates
-
Decision published.
-
First published.